Skip to main content

Requirements for Batch Production Records

BayBiotech.NET
Batch Production Record is an example of a GMP document and is designed to standardize the process and provides with lot-specific information.
GMP Requirements for Batch Records are defined under following FDA regulations:
 Master Batch Record 21 CFR 211.188
 21 CFR 211.194—Laboratory Records
 21 CFR 211.194—Review by the Quality Control Unit
A batch production record must be established every time a batch is manufactured and must include the following:
Requirements for Laboratory Operations

•Establish and follow written procedures for laboratory operations
•Use adequate laboratory facilities
•Requirements for Laboratory control processes
•Methods for testing and examination
Requirements for Manufacturing Operations
•Establish and follow written procedures for manufacturing operations
•Ensure product specifications are consistent
•Adequate sanitation principles
•Prevent contamination
•Appropriate disposition of rejected or unsuitable dietary supplements
•Requirements for repackaging and relabeling
•Packaged and labeled supplements rejected for distribution
•Record Keeping
•Establish and follow written procedures for holding and distributing operations
•Requirements to hold components, supplements, packaging and labels
•Requirements for in-process materials
•Requirements for reserve samples
•Distribution requirements to protect against contamination and deterioration

The content produced here are part of the QA/Regulatory training taken from Kriger Research Center.

Comments

Popular posts from this blog

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!

Harmonization by Doing (HBD): Japan & U.S. Collaboration

BayBiotech.NET HBD is an international cooperative effort by Japan and US for regulatory convergence for Medical Devices. The efforts are focused on to develop global clinical trials and address regulatory barriers for timely device approvals. To address the needs for additional evaluation, the HBD initiative is a pilot project launched jointly by FDA and MHLW-PMDA for the premarket review of device cardiovascular technology. Instead of taking a theoretical approach to harmonization, HBD is focused on Proof of concept by utilizing parallel development, application submissions and review of actual medical device projects. HBD Study intends to collect and analyze regulatory submission data from multiple applications in the U.S. and Japan. The purpose of the study is to further understand differences that may exist with format and content, to define best practices and to improve globally harmonized processes. To read more about the HBD program, follow the link: http://www.fda.gov/M...